Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

N/A

2(66.7%)

Phase 2

1(33.3%)

3Total

N/A(2)

Phase 2(1)

Loading network data...

Showing 5 of 5 trials

Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)

Role: collaborator

Neuropathic Pain in Jamaicans With Sickle Cell Disease

Role: collaborator

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

Role: collaborator

Effect of an Emollient Cream Containing 0.5% Cannabidiol and 1% Hemp Oil in the Hydration and Erythema of the Skin

Role: lead

Effect of a Facial Cream Containing Cannabidiol and Hemp Oil on Skin Hydration and Acne-prone Skin

Role: lead

All 5 trials loaded